Skip to content

Impact of Free Mobility on FDG Uptake in PET Scans

Impact of Free Mobility on FDG Uptake During a PET Scan: Randomized Controlled Non-inferiority Study

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06799819
Acronym
MOBITEP
Enrollment
284
Registered
2025-01-29
Start date
2025-04-30
Completion date
2026-06-15
Last updated
2026-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neoplasms, Whole Body Imaging

Keywords

FDG PET, muscular uptake, image quality, Diagnostic Technics and Procedures

Brief summary

Positron Emission Tomography (PET) is a rather long examination (around 2 hours), involving an injection of 18F-Fluorodeoxyglucose (FDG), which requires the patient to rest for 1 hour between the injection and the start of imaging. Some hospitals allow the patient to sit, read or use the telephone, but none allow the patient to move freely after injection, hence the interest of this work. The aim of this study is to demonstrate that free mobilization of the patient following 18F-FDG injection does not result in any significant difference in imaging quality (particularly muscular fixations), and therefore a medical interpretation identical to that of a patient who remains at rest.

Detailed description

FDG-PET is a fairly long scan involving an injection of 18F-FDG. Because of the fear of muscular fixations, the guidelines recommend for rest between injection and image acquisition. Indeed, some studies have demonstrated significant muscular uptake of the radiopharmaceutical in the event of major muscular effort prior to the examination. However, to investigators knowledge, the effect of free mobilization between injection and scan has not been evaluated. The aim of this study is to demonstrate that free mobilization of the participant after 18F-FDG injection does not result in a significant difference in imaging quality (especially muscular fixation) and therefore in a medical interpretation identical to that of a patient who remains at rest. Investigators also want to assess the impact on participant comfort and stress. Each participant will receive an information leaflet with his or her examination appointment. On arrival in the department, after the study has been explained by the investigator and the participant has had all his questions answered, participant may accept inclusion by signing a consent form or refuse it. Once the inclusion of the participant has been validated, the randomisation will be done: the control group will benefit from the standard examination procedure (rest after FDG injection) and the experimental group will benefit from the study procedure (free mobility after FDG injection). The participant will complete a questionnaire on level of stress and comfort after the imaging procedure, and the nuclear physician will provide a blind interpretation. A review of all blinded examinations will be carried out by two nuclear physicians to establish an examination quality score. An intermediate analysis will be carried out when 50% of exclusions have been reached to stop the study if the management studied is detrimental compared with standard management.

Interventions

BEHAVIORALMobility group

Free mobility between FDG injection and scanning (without exiting the Nuclear Medicine Department)

Sponsors

Centre Hospitalier Régional d'Orléans
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Investigator, Outcomes Assessor)

Masking description

Blind analysis of the imaging

Intervention model description

Prospective, randomized, controlled, comparative, single-center, non-inferiority and single-blind (for the evaluator) study.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Adults 2. Patient referred for FDG PET (excluding brain PET) and carried out on an outpatient basis.

Exclusion criteria

1. Bedridden patients 2. Protected person (under guardianship or curatorship) 3. Persons under court protection 4. Persons deprived of liberty 5. Persons not affiliated to a social security scheme 6. Pregnant or breast-feeding woman

Design outcomes

Primary

MeasureTime frameDescription
Visual image quality score (in terms of muscle fixations)Day 0The visual quality of the images will be the main evaluation criterion. An overall examination quality score will be given by the investigator for each patient, using a 3-point Likert scale: 1. no muscular fixation (interpretable examination) 2. some muscular fixations that do not interfere with medical interpretation (interpretable examination) 3. significant muscular fixations that make the examination uninterpretable. The main evaluation criterion will be the proportion of score 1 in the two groups of patients (with and without strict rest), bearing in mind that images scored 3 are very rare.

Secondary

MeasureTime frameDescription
Cervical SUV maxDay 0
Lumbosacral SUV maxDay 0
Improving patient comfortDay 0Item-by-item comparisons are made between the two groups
Level of stressDay 0Item-by-item comparisons are made between the two groups
Examination quality scoreDay 0Factors that may influence the examination quality score will be analyzed.

Countries

France

Contacts

PRINCIPAL_INVESTIGATORAdeline FRAT

CHU Orléans

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 19, 2026